Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An assessor blind, randomized, 2-way crossover, two period, single-dose, phase I, active controlled, pharmacokinetic and pharmacodynamic study comparing pegfilgrastim biosimilar with Neulasta® of Amgen (US licensed product) in healthy adult human subjects.

Next Previous
X
Search
Trial Profile

An assessor blind, randomized, 2-way crossover, two period, single-dose, phase I, active controlled, pharmacokinetic and pharmacodynamic study comparing pegfilgrastim biosimilar with Neulasta® of Amgen (US licensed product) in healthy adult human subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Neutropenia
  • Focus Pharmacodynamics; Pharmacokinetics

    • Most Recent Events

    • 27 Jul 2018 According to Accord Healthcare media release, The CHMP positive opinion was based on Pelgraz's substantial clinical development programme, which supported its biosimilarity with Neulasta through a Phase I, randomised, assessor-blinded PK/PD study in healthy volunteers, and a Phase III study of patients with breast cancer (stage IIa, IIb, or IIIa) on TAC (docetaxel, doxorubicin, cyclophosphamide).
    • 14 Nov 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top